2017 Chemotherapy Drug Development 
pharmaphorum
APRIL 27, 2021
On Wednesday (28 April), the focus will shift to Keytruda and Tecentriq as first-line treatments for UC patients unable to be treated with cisplatin-containing chemotherapy – which got the go-ahead in 2017 and 2018, respectively.
pharmaphorum
JUNE 8, 2021
All these factors will support the growth of in-house R&D-driven pharmaceutical companies and bring more innovative drugs to Asian markets.”. Chemotherapy still accounted for 72.6% Mei says that oncology is one of the key region-specific unmet medical needs Antengene is hoping to address with innovative drugs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
JUNE 23, 2021
Savolitinib will be sold as Orpathys for the treatment of NSCLC patients whose tumours have MET exon 14 skipping mutations who have previously had systemic treatment or are unable to receive chemotherapy. The big question for the Fosun/Kite CAR-T is pricing and whether the government will help out any.
Pharmaceutical Technology
AUGUST 12, 2022
They were first licensed for use in 2017 for two forms of blood cancer, acute lymphoblastic leukemia (ALL), and B-cell lymphoma (BCL). The standard first-line treatment for DLBCL is a chemotherapy regimen, alongside the monoclonal antibody rituximab. Overall, the global CAR-T cell market for all indications was worth $1.7
European Pharmaceutical Review
JULY 5, 2022
The availability of oral chemotherapy treatments would provide stomach cancer patients with the option of more efficacious drugs with improved tolerability in a more convenient dosage format” The poor clinical outcomes of stomach cancer make it a key target for drug development. New hope for stomach cancer patients.
pharmaphorum
JUNE 9, 2022
In order to reduce the global healthcare impact of the evolving AMR situation, companies such as Micreos Pharmaceuticals are taking a novel and highly innovative approach to antibacterial drug development by developing targeted antimicrobial products. Antimicrobial Agents and Chemotherapy 2022. References. Herpers, P.
Pharmaceutical Technology
AUGUST 1, 2022
If left unchecked, it may soon not be possible to use antibiotics as prophylaxis for immunocompromised patients during chemotherapy or organ transplants. Moreover, without effective antibiotics, epidemic bacterial infections will become common in the developed world and the risk of infections after surgery will increase.
Expert insights. Personalized for you.
90 
Let's personalize your content